The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.

Sometimes, people with iron deficiency anemia don't respond to treatment with iron supplementation and may go months to years with little to no improvement in anemia. This can happen if the dose is ...

ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –– ...